Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive entities : Sanofi save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
lung drug cancer treatment application therapeutics
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.8M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -1.77%
lung cancer treatment therapeutics china
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $42.31 -2.76% -2.84% 230K
|
|
| O: 0.0%
H: 2.86%
C: 0.13%
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
nanobody fda positive ema program
Achondroplasia Treatment Drug Market to Register Positive Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Ascendis Pharma, QED Therapeutics (BridgeBio), Novartis, Sanofi, RIBOMIC
Published: 2024-01-09 (Crawled : 22:00) - prnewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.13%
H: 0.0%
C: 0.0%
drug companies achondroplasia positive treatment key therapeutics growth market
Press Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
Published: 2023-12-15 (Crawled : 06:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
first positive treatment ema africa
Metastatic Prostate Cancer Market to Exhibit Positive Growth at a CAGR of 22% and 7.5% for mHSPC and mCRPC, respectively During the Study Period (2019-2032), Assesses DelveInsight
Published: 2023-12-13 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.8%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
positive cancer growth study market
Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period (2019-2032), Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda
Published: 2023-12-12 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
UCBJY | $64.07 -4.38% 72K
|
Manufacturing
|
| O: -0.62%
H: 1.01%
C: 1.01%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
CPRX | $15.35 -4.06% -4.23% 1.4M
|
Health Technology
|
| O: -0.37%
H: 5.49%
C: 5.49%
companies positive growth study market
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Published: 2023-12-07 (Crawled : 01:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.66%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.19%
H: 0.0%
C: 0.0%
positive ongoing collaboration study
Metastatic HER2-Positive Breast Cancer Market to Grow by 2032 at a 5.2% CAGR | DelveInsight
Published: 2023-11-29 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
IMMP | News | $2.205 -2.43% -2.73% 270K
|
Health Technology
|
| O: 3.13%
H: 1.52%
C: 0.51%
breast cancer market
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
dupixent positive copd results sanofi
Dupixent® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Published: 2023-11-27 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.36%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.04%
H: 0.17%
C: 0.11%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 0.46%
H: 0.37%
C: -0.49%
dupixent fda disease approved positive copd potential submission
Generalized Anxiety Disorder Treatment Market to Showcase Positive Growth During the Forecast Period (2023-2032), Assesses DelveInsight | Key Players - MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics
Published: 2023-10-30 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: -3.51%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -1.67%
H: 3.16%
C: 2.75%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 2.61%
H: 0.0%
C: 0.0%
positive treatment growth market
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-10-25 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.4%
H: 1.29%
C: 1.29%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.43%
H: 0.64%
C: -0.09%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -1.28%
H: 0.58%
C: -1.46%
disease alzheimer’s positive results
BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 15:30) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
BNTX | $86.19 -0.24% -0.24% 580K
|
Health Technology
|
| O: -2.24%
H: 7.12%
C: 4.11%
bnt211 candidate congress tumors positive update cell car-t therapy
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
Published: 2023-10-11 (Crawled : 14:00) - globenewswire.com
MLTX | $42.31 -2.76% -2.84% 230K
|
|
| O: 1.63%
H: 1.95%
C: -8.55%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
nanobody congress positive trial
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
Published: 2023-10-04 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
MRNA S | $102.015 -1.38% -1.4% 1.7M
|
Health Technology
|
| O: 1.48%
H: 0.2%
C: -0.33%
rna-1083 covid-19 vaccine positive influenza
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published: 2023-09-13 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.8%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.99%
H: 0.0%
C: 0.0%
fda positive treatment meeting
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.